|
1
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Z, Miao L, Xin X, et al:
Underexpressed CNDP2 participates in gastric cancer growth
inhibition through activating the MAPK signaling pathway. Mol Med.
20:17–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sampieri CL, León-Córdoba K and
Remes-Troche JM: Matrix metalloproteinases and their tissue
inhibitors in gastric cancer as molecular markers. J Cancer Res
Ther. 9:356–363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Canavese G, Candelaresi G, Castellano I
and Mano MP: Expression of proteoglycan versican in in situ breast
lesions: relations between stromal changes, histotype, and
invasion. Pathol Res Pract. 207:97–103. 2011. View Article : Google Scholar
|
|
6
|
Lorenzo P, Aspberg A, Onnerfjord P, et al:
Identification and characterization of asporin. A novel member of
the leucine-rich repeat protein family closely related to decorin
and biglycan. J Biol Chem. 276:12201–12211. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Satoyoshi R, Kuriyama S, Aiba N, et al:
Asporin activates coordinated invasion of scirrhous gastric cancer
and cancer-associated fibroblasts. Oncogene. 34:650–660. 2015.
View Article : Google Scholar
|
|
8
|
Theocharis AD, Vynios DH,
Papageorgakopoulou N, et al: Altered content composition and
structure of glycosaminoglycans and proteoglycans in gastric
carcinoma. Int J Biochem Cell Biol. 35:376–390. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu L, Duan YT, Li JF, et al: Biglycan
enhances gastric cancer invasion by activating FAK signaling
pathway. Oncotarget. 5:1885–1896. 2014.PubMed/NCBI
|
|
10
|
Wang B, Li GX, Zhang SG, et al: Biglycan
expression correlates with aggressiveness and poor prognosis of
gastric cancer. Exp Biol Med (Maywood). 236:1247–1253. 2011.
View Article : Google Scholar
|
|
11
|
Ansari D, Aronsson L, Sasor A, et al: The
role of quantitative mass spectrometry in the discovery of
pancreatic cancer biomarkers for translational science. J Transl
Med. 12:872014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Turtoi A, Musmeci D, Wang Y, et al:
Identification of novel accessible proteins bearing diagnostic and
therapeutic potential in human pancreatic ductal adenocarcinoma. J
Proteome Res. 10:4302–4313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klee EW, Bondar OP, Goodmanson MK, et al:
Candidate serum biomarkers for prostate adenocarcinoma identified
by mRNA differences in prostate tissue and verified with protein
measurements in tissue and blood. Clin Chem. 58:599–609. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Turashvili G, Bouchal J, Baumforth K, et
al: Novel markers for differentiation of lobular and ductal
invasive breast carcinomas by laser microdissection and microarray
analysis. BMC Cancer. 7:552007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kizawa H, Kou I, Iida A, et al: An
aspartic acid repeat polymorphism in asporin inhibits
chondrogenesis and increases susceptibility to osteoarthritis. Nat
Genet. 37:138–144. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kopp R, Rothbauer E, Ruge M, et al:
Clinical implications of the EGF receptor/ligand system for tumor
progression and survival in gastrointestinal carcinomas: evidence
for new therapeutic options. Recent Results Cancer Res.
162:115–132. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moon WS, Tarnawski AS, Chai J, et al:
Reduced expression of epidermal growth factor receptor related
protein in gastric cancer. Gut. 54:201–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashktorab H, Daremipouran M, Wilson M, et
al: Transactivation of the EGFR by AP-1 is induced by Helicobacter
pylori in gastric cancer. Am J Gastroenterol. 102:2135–2146. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hwang YP, Yun HJ, Choi JH, et al:
Suppression of EGF-induced tumor cell migration and matrix
metalloproteinase-9 expression by capsaicin via the inhibition of
EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling.
Mol Nutr Food Res. 55:594–605. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Murphy KM, Ranganathan V, Farnsworth ML,
et al: Bcl-2 inhibits Bax translocation from cytosol to
mitochondria during drug-induced apoptosis of human tumor cells.
Cell Death Differ. 7:102–111. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wobus M, Rangwala R, Sheyn I, et al: CD44
associates with EGFR and erbB2 in metastasizing mammary carcinoma
cells. Appl Immunohistochem Mol Morphol. 10:34–39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gurgel DC, Valença-Junior JT, Dornelas CA,
et al: Immuno expression of metalloproteinases 2 and 14 and TIMP-2
inhibitor in main types of primary gastric carcinomas and lymph
node metastasis. Pathol Oncol Res. 21:73–81. 2015. View Article : Google Scholar
|
|
23
|
Zhang Z, Zhang J, Miao L, et al:
Interleukin-11 promotes the progress of gastric carcinoma via
abnormally expressed versican. Int J Biol Sci. 8:383–393. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmidt M and Lichtner RB: EGF receptor
targeting in therapy-resistant human tumors. Drug Resist Updat.
5:11–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kolch W: Coordinating ERK/MAPK signalling
through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 6:827–837.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Merline R, Schaefer RM and Schaefer L: The
matricellular functions of small leucine-rich proteoglycans
(SLRPs). J Cell Commun Signal. 3:323–335. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi M, Zheng D, Sun L, et al: XB130
promotes proliferation and invasion of gastric cancer cells. J
Transl Med. 12:12014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Khurana SS, Riehl TE, Moore BD, et al: The
hyaluronic acid receptor CD44 coordinates normal and metaplastic
gastric epithelial progenitor cell proliferation. J Biol Chem.
288:16085–16097. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Łukaszewicz-Zając M, Mroczko B,
Guzińska-Ustymowicz K, et al: Matrix metalloproteinase 2 (MMP-2)
and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients.
Adv Med Sci. 58:235–243. 2013. View Article : Google Scholar
|
|
30
|
Hwang TL, Changchien TT, Wang CC and Wu
CM: Claudin-4 expression in gastric cancer cells enhances the
invasion and is associated with the increased level of matrix
metalloproteinase-2 and -9 expression. Oncol Lett. 8:1367–1371.
2014.PubMed/NCBI
|
|
31
|
Song YQ, Cheung KM, Ho DW, et al:
Association of the asporin D14 allele with lumbar-disc degeneration
in Asians. Am J Hum Genet. 82:744–747. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tomoeda M, Yamada S, Shirai H, et al:
PLAP-1/asporin inhibits activation of BMP receptor via its
leucine-rich repeat motif. Biochem Biophys Res Commun. 371:191–196.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cabello-Verrugio C and Brandan E: A novel
modulatory mechanism of transforming growth factor-beta signaling
through decorin and LRP-1. J Biol Chem. 282:18842–18850. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zafiropoulos A and Tzanakakis GN:
Decorin-mediated effects in cancer cell biology. Connect Tissue
Res. 49:244–248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mohan RR, Tovey JC, Gupta R, et al:
Decorin biology, expression, function and therapy in the cornea.
Curr Mol Med. 11:110–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morcavallo A, Buraschi S, Xu SQ, et al:
Decorin differentially modulates the activity of insulin receptor
isoform A ligands. Matrix Biol. 35:82–90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goldoni S, Iozzo RA, Kay P, et al: A
soluble ectodomain of LRIG1 inhibits cancer cell growth by
attenuating basal and ligand-dependent EGFR activity. Oncogene.
26:368–381. 2007. View Article : Google Scholar
|
|
38
|
Judd NP, Winkler AE, Murillo-Sauca O, et
al: ERK1/2 regulation of CD44 modulates oral cancer aggressiveness.
Cancer Res. 72:365–374. 2012. View Article : Google Scholar :
|
|
39
|
Chen Y, Zheng L, Liu J, et al: Shikonin
inhibits prostate cancer cells metastasis by reducing matrix
metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2
pathways. Int Immunopharmacol. 21:447–455. 2014. View Article : Google Scholar : PubMed/NCBI
|
